Bristol-Myers Q1 top line up 12%; Opdivo sales up 60%; earnings up 32%; EPS guidance raised; shares ahead 4% premarket

|About: Bristol-Myers Squibb C... (BMY)|By:, SA News Editor

Bristol-Myers Squibb (NYSE:BMY) Q1 results ($M): Total Revenues: 4,929 (+12.3%); Product Sales: 4,580 (+15.5%).

Net Income: 1,574 (+31.7%); Non-GAAP Net Income: 1,400 (+13.4%); EPS: 0.94 (+32.4%); Non-GAAP EPS: 0.84 (+13.5%).

Key Product Sales: Opdivo: 1,127 (+60.1%); Eliquis: 1,101 (+50.0%); Orencia; 535 (+12.6%); Sprycel: 463 (+13.8%); Yervoy: 330 (+25.5%); Hep C Franchise: 162 (-62.1%).

2017 Guidance: Revenue growth: mid-single digit; EPS: $2.72 - 2.87 from $2.47 - 2.67; Non-GAAP EPS: $2.85 - 3.00 from $2.70 - 2.90.

Shares are up 4% premarket on increased volume.